Contract Manufacturing, DNA, Licensing and Life Science

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Contract Manufacturing

DNA

Licensing

Life Science

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA

DNA Vaccination Vaccine Immune Response

The challenges and trends of cell & gene therapies

Drug Discovery World

SEPTEMBER 6, 2022

Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. The Skills Demand Survey Report presents a lack of graduate life sciences apprenticeship programmes as a key barrier. Workforce .

Gene Therapy

Gene Therapy Gene Manufacturing Medicine

Clinical Research Informer

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The challenges and trends of cell & gene therapies

Stay Connected